New York, New York--(Newsfile Corp. - November 12, 2026) - Investors who suffered losses on Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) stock may have claims to recover those losses. Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors that a federal securities class action has been filed on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Ardelyx securities between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Investors who wish to serve as lead plaintiff must move the Court no later than November 16, 2026.

Investors with losses on Ardelyx securities can contact Faruqi & Faruqi partner Josh Wilson about the Ardelyx class action to learn about their legal rights and options.

Key facts for Ardelyx investors

• Class Period: between January 13, 2025 and August 6, 2026

• Lead plaintiff deadline: November 16, 2026

• Disclosure: August 6, 2026

• Stock drop: $0.87 per share, or 18%

What happened?

On August 6, 2026, Ardelyx issued a press release a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction on significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, Defendants withdrew their long-term XPHOZAH revenue guidance due to "evolving market dynamics" and uncertainty regarding future growth projections. On this news, the price of Ardelyx's common stock declined dramatically. From a closing market price of $4.87 per share on August 6, 2026, Ardelyx's stock price fell to $4.00 per share on August 7, 2026, a decline of about 18% in the span of just a single day.

"Ardelyx stock fell 18% on August 7, 2026 after the August 6, 2026 disclosure described in the complaint. The complaint alleges that investors bought Ardelyx shares during the Class Period without the full picture," said Josh Wilson, a partner at Faruqi & Faruqi, LLP.

What does the complaint allege?

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: the true state of Ardelyx's commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment.

Next steps for Ardelyx investors

Faruqi & Faruqi, LLP is reviewing potential claims on behalf of Ardelyx investors. Investors with losses can visit www.faruqilaw.com/ARDX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss the Ardelyx class action.

If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Common questions from Ardelyx investors

Who is eligible? Investors who purchased or otherwise acquired Ardelyx securities between January 13, 2025 and August 6, 2026 and lost money may have claims, and can contact the firm to learn whether the Ardelyx class action affects them.

What is a securities class action? A lawsuit brought on behalf of a group of investors who bought shares at prices alleged to have been inflated by false or misleading statements, in violation of the federal securities laws. The Ardelyx class action alleges that the Company and its executives made such statements.

Has a lawsuit been filed? Yes. A federal securities class action has been filed against Ardelyx. Investors who wish to serve as lead plaintiff must move the Court by November 16, 2026. Investors who do nothing remain absent class members, and serving as lead plaintiff is not required to share in any recovery.

Does it cost anything to contact the firm? No. Investors who purchased Ardelyx securities during the Class Period may contact Faruqi & Faruqi, LLP to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Whistleblower notice

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ardelyx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Individuals with original information may also consider the SEC Whistleblower Program, which can award whistleblowers 10 to 30 percent of the monetary sanctions collected in a successful SEC enforcement action when those sanctions exceed $1 million.

About Faruqi & Faruqi, LLP

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Related links

• Ardelyx class action, Faruqi & Faruqi, LLP

• Ardelyx, Inc. SEC filings index, EDGAR

• SEC Whistleblower Program

• Faruqi & Faruqi, LLP

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323580

Source: Faruqi & Faruqi LLP